The EDEM3 Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human NCI-H1299 non-small cell lung adenocarcinoma cell line. This product provides a heterogeneous pool of cells carrying disruptions in the EDEM3 gene, enabling functional studies of endoplasmic reticulum-associated degradation (ERAD) and the unfolded protein response (UPR). The polyclonal nature retains genetic diversity within the knockout population, reflecting population-level effects of EDEM3 loss without clonal artifacts. It serves as a versatile model for examining the consequences of impaired glycoprotein quality control in a lung cancer background.
The NCI-H1299 cell line is an epithelial cell line established from a metastatic lymph node of a 43-year-old Caucasian male with non-small cell lung cancer. Notably, it harbors a p53-null status, which contributes to its oncogenic phenotype and resistance to apoptosis. Widely employed in lung adenocarcinoma research, NCI-H1299 cells exhibit characteristic features including rapid proliferation and metastatic potential, making them a relevant platform for studying tumor biology and therapeutic interventions. The loss of p53 also impacts cellular stress responses, providing a unique context for investigating ER stress pathways.
EDEM3 encodes an ER-resident alpha-1,2-mannosidase that trims terminal mannose residues from misfolded N-linked glycoproteins, generating a terminal ??1,6-linked mannose moiety. This glycan signal is recognized by OS9 and XTP3-B, which deliver substrates to the HRD1-SEL1L retrotranslocation complex. The misfolded proteins are then ubiquitinated by HRD1 and extracted to the cytosol for degradation by the 26S proteasome, a process requiring p97/VCP. EDEM3 expression is transcriptionally controlled by ATF6, XBP1s, and the PERK-eIF2??-ATF4 axis. Its downstream effects include reduced IRE1?? signaling and attenuated CHOP expression, mitigating ER stress. EDEM3 also interacts with SEL1L, VIMP, Derlin-1, and calnexin/calreticulin to ensure efficient clearance of misfolded clients.
In the context of NCI-H1299 lung adenocarcinoma cells, EDEM3 knockout provides a critical tool for dissecting the interplay between ER protein quality control and oncogenic signaling. Given the high secretory demands and inherent ER stress in cancer cells, disruption of EDEM3 may sensitize these p53-null cells to agents that exacerbate ER stress, such as tunicamycin or thapsigargin. This model enables the study of how impaired glycoprotein degradation impacts tumor cell survival, proliferation, and sensitivity to chemotherapy. Furthermore, it allows investigation into potential synthetic lethality interactions between ERAD deficiency and the p53-null status, offering insights into novel therapeutic vulnerabilities in lung cancer.
The EDEM3 Knockout NCI-H1299 Polyclonal Cells are suitable for a wide array of research applications, including mechanistic studies of ERAD and UPR pathways, functional validation of EDEM3 as a therapeutic target, and screening for small-molecule modulators of glycoprotein quality control. Representative assays compatible with this model include western blotting for UPR markers (e.g., BiP, CHOP), RT-qPCR analysis of XBP1 splicing and ATF4 induction, cycloheximide chase to assess protein turnover, immunofluorescence for ER morphology, and clonogenic survival assays under ER stress conditions. In vivo, these cells can be utilized in xenograft tumor models to evaluate the impact of EDEM3 loss on tumor growth and drug response. For further information, please contact Ascent Research.
